REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,803.50
Bid: 1,803.00
Ask: 1,803.50
Change: -6.50 (-0.36%)
Spread: 0.50 (0.028%)
Open: 1,805.00
High: 1,811.00
Low: 1,797.00
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Ignoring WHO call, major nations stick to vaccine booster plans

Thu, 05th Aug 2021 09:09

* Global body disapproves of boosters until more people
vaccinated

* Some rich nations going ahead anyway to fend off Delta
variant

* Elderly and vulnerable to benefit first from booster shots

* Low-income nations suffer from lack of vaccine supplies
(Adds details throughout)

By Sudip Kar-Gupta and Caroline Copley

PARIS/BERLIN, Aug 5 (Reuters) - Germany, France and Israel
will go ahead with plans to administer COVID-19 vaccine
boosters, disregarding an appeal by the World Health
Organisation to hold off until more people are vaccinated around
the world.

The decision to press ahead with booster shots despite the
WHO's strongest statement yet highlights the huge inequities in
responses to the pandemic as richer nations ramp up programmes
to protect citizens from the more infectious Delta variant.

French President Emmanuel Macron said France was working on
rolling out third doses to the elderly and vulnerable from
September.

Germany intends to give boosters to immunocompromised
patients, the very elderly and nursing home residents from
September, the health ministry said.

Israeli Prime Minister Naftali Bennett urged older citizens
to get a third shot after the government last month kicked off a
campaign to give booster doses.

"Whoever is over the age of 60, and has yet to receive the
third dose of the vaccine, is six times more susceptible to
severe illness and - heaven forbid - death," Bennett said in a
statement.

WHO chief Tedros Adhanom Ghebreyesus called on Wednesday for
a halt to boosters until at least the end of September, saying
it was unacceptable for rich countries to use more of the global
vaccine supply.

INEQUALITIES MOUNT

High-income countries administered around 50 doses for every
100 people in May, and that number has since doubled, according
to WHO. Low-income countries have only been able to administer
1.5 doses for every 100 people, due to lack of supplies.

"I understand the concern of all governments to protect
their people from the Delta variant. But we cannot accept
countries that have already used most of the global supply of
vaccines using even more of it," Tedros said.

Germany rejected those accusations, saying it would also
donate at least 30 million vaccine doses to poorer countries.

"We want to provide the vulnerable groups in Germany with a
precautionary third vaccination and at the same time support the
vaccination of as many people in the world as possible," the
health ministry said.

Following Tedros' comments, the White House said on
Wednesday it was prepared to provide booster shots if needed,
suggesting it would not heed the WHO's call either.

Pfizer has said boosters are most likely needed
because of waning antibody responses, particularly after six
months.

U.S. health regulators have said that more scientific
evidence is needed to be certain boosters are needed, but have
indicated they believe a third shot may be needed for people
with compromised immune systems.

Macron's government is trying to step up France's
vaccination programme as the country faces a fourth wave of the
virus and street demonstrations in protest against the
government's COVID policies.

France and Germany have so far given at least one dose of a
COVID-19 vaccine to 64.5% and 62% of their respective
populations, with 49% of the French and 53% of Germans fully
vaccinated.

(Reporting by Sudip Kar-Gupta and Nicolas Delame in Paris,
Alexander Ratz and Caroline Copley in Berlin; Editing by Nick
Macfie, Josephine Mason, Andrew Cawthorne)

More News
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.